Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Subjects With Pyruvate Kinase Deficiency

NCT06422351 is registered in ClinicalTrials.gov with Rocket Pharmaceuticals Inc. as lead sponsor.

NCT NCT06422351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06422351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced With a Lentiviral Vector Carrying the Codon Optimized Red Cell Pyruvate Kinase (coRPK) Gene in Subjects With Pyruvate Kinase Deficiency
Lead sponsor
Rocket Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Suspended
Start date
April 30, 2026
Completion date
January 31, 2029
Enrollment
10 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

pyruvate kinase deficiency